[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-adult-females\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-adult-females":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,43,68,92,118,150,178],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100632265","phase-4-reversible-effects-of-oral-contraceptive-removal-on-serotonergic-neurotransmission-100632265",false,"NCT07511439","Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission","REVERSE","Inclusion Criteria:\n\n1. Healthy women (assigned female at birth) at 18-39 years of age\n2. Currently using a second-generation combined oral contraceptive containing 150 ug levonorgestrel and 30 ug ethinylestradiol for at least 3 months\n\nExclusion Criteria:\n\n1. Current or previous neurological or psychiatric disease, severe somatic disease, or consumption of medical drugs (including psychoactive medication) likely to influence the test results\n2. Non-fluent in Danish or pronounced visual or auditory impairments\n3. Current or past learning disability\n4. Pregnancy within the last year or previous pregnancy lasting into second or third trimester\n5. A wish to become pregnant within the following 12 months\n6. Participation in experiments with exposure to radioactivity (\\> 10 mSv) within the last year or significant occupational exposure to radioactivity\n7. Contraindications for MRI (pacemaker, metal implants, claustrophobia)\n8. A history of head injury or concussion resulting in loss of consciousness for more than 2 min\n9. Alcohol or drug abuse\n10. Drug use other than tobacco and alcohol within the last 30 days\n11. Cannabis \\> 50 x lifetime\n12. Recreational drugs other than cannabis \\> 10 x lifetime (for each substance)\n13. Nicotine addiction\n14. Non-compliance to COC within the last 3 months (i.e., \\> 2 missed pills in a cycle)\n15. Contraindication for use of combined oral contraception",true,"FEMALE","18 Years","39 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this study is to learn about potential reversible effects of combined oral contraceptive (COC) use on the serotonergic brain system. The main question it aims to answer is:\n\n\\- If COC discontinuation results in an increase in serotonin 4 receptor binding in caudate, putamen, and hippocampus measured with Positron Emission Tomography from baseline to follow-up ≥ week 8 after discontinuation.\n\nThe secondary question it aims to answer is:\n\n\\- Over what timeframe the serotonin 4 receptor binding is restored after COC discontinuation to the level previously seen in a group of premenopausal women who had not used hormonal contraception before.\n\nResearchers will compare discontinuation with continuation of a 2nd generation COC containing 150 ug levonorgestrel and 30 microgram to see if COC discontinuation results in an increased serotonin 4 receptor level in the brain.\n\n\\-\n\nParticipants will:\n\n* Be randomized to discontinue or continue their COC use for 1-52 weeks.\n* Undergo an investigational program including brain scans, biological sampling, and neuropsychological testing at baseline and at follow-up.\n\nThe study uses a group sequential design with two sequential analyses planned, including an interim analysis after 60% of the brain scans have been acquired, which will be used to decide the timing of the last 40% of the scans - this is performed to best determine when the recovery of the serotonin 4 receptor level occurs.",[28,29],"The Focus of the Study is to Investigate Reversible Effects of Combined Oral Contraceptive Use on Serotonergic Neurotransmission","Healthy Adult Females","RECRUITING","2026-06-30",{"date":33,"type":34},"2026-07-02","ACTUAL",{"date":36,"type":34},"2026-04-23",{"date":38,"type":22},"2030-12-31",{"name":40,"class":41},"Rigshospitalet, Denmark","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":64,"leadSponsor":66,"locationsCount":42},"100642210","effect-of-pre-exercise-inhalation-of-molecular-hydrogen-on-metabolic-response-during-graded-exercise-in-healthy-women-100642210","NCT07644000","Effect of Pre-exercise Inhalation of Molecular Hydrogen on Metabolic Response During Graded Exercise in Healthy Women","Effect of Repeated Pre-exercise Inhalation of Molecular Hydrogen on Metabolic Response During Graded Exercise in Healthy Women: A Randomized, Double-blind, Placebo-controlled Crossover Trial","Inclusion Criteria:\n\n* Healthy female participants.\n* Regular menstrual cycle with exercise testing scheduled outside the menstrual phase.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* History or presence of cardiovascular disease.\n* History or presence of respiratory disease.\n* Regular use of medications affecting metabolism.\n* Use of dietary supplements affecting metabolism within 14 days prior to intervention.\n* Strenuous physical activity within 24 hours prior to exercise testing.\n* Any contraindication to exercise testing or study participation determined by a physician.","30 Years",{"count":52,"type":22},22,[54],"NA","The goal of this clinical trial is to evaluate if molecular hydrogen can reduce the metabolic response during graded exercise in healthy women aged 18-30 years. The main questions it aims to answer are:\n\n* Does molecular hydrogen reduce the respiratory exchange ratio?\n* Does molecular hydrogen reduce oxygen uptake?\n\nResearchers will compare molecular hydrogen to a placebo (ambient air containing no molecular hydrogen) to see if molecular hydrogen reduces the metabolic response.\n\nParticipants will:\n\n* Inhale molecular hydrogen for 60 minutes each day for 7 days.\n* Undergo an exercise testing twice after a two-week washout period.",[29],[58,59],"molecular hydrogen","metabolic response","2026-06-22",{"date":62,"type":34},"2026-06-25",{"date":60,"type":34},{"date":65,"type":22},"2026-12",{"name":67,"class":41},"Palacky University",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":42},"100641929","apply-biphasic-ivm-for-poseidon-group-1-100641929","NCT07632300","Apply Biphasic IVM for POSEIDON Group 1","Efficacy and Safety of Biphasic IVM in Low Prognosis Patients Classified as Poseidon Group 1A","POSEIDON-Ia","Inclusion Criteria:\n\n* Women aged 18 - \\\u003C 35 years\n* At least one IVF cycle have been failed and classified as having a poor response to POSEIDON group Ia.\n* POSEIDON group Ia ( \\\u003C 35 age; AMH \\>= 1.2 ng\u002Fml and\u002For AFC \\>=5 antral follicles; have \\\u003C 4 oocytes was retrieved at previous IVF cycle)\n* Agree to apply biphasic-IVM treatment.\n* Agree to freeze all embryos and to transfer the frozen embryos afterward.\n* Agree to participate in the study.\n\nExclusion Criteria:\n\n* Egg-donation cycle\n* Uterine abnormalities: adenomyosis, large uterine fibroids (≥5 cm), bicornuate uterus, uterine adhesions.\n* Sperm surgical (PESA, TESE, mTESE)\n* PGT","35 Years",{"count":78,"type":22},25,[54],"The goal of this clinical trial is to learn if biphasic In Vitro Maturation (IVM) works to help young women who produce very few oocytes after controlled ovarian stimulation. The study focuses on women under age 35 who have a good number of follicles in their ovaries but do not respond well to standard ovarian stimulation by Gonadotropin (known as POSEIDON Group 1a).\n\nThe main questions it aims to answer are:\n\nHow many mature oocytes can be obtain after biphasic -VM? Researchers will use biphasic-IVM system to see if it can bypass the problems these patients face with standard treatments, such as high costs and the risk of medical complications like Ovarian Hyperstimulation Syndrome (OHSS).\n\nParticipants will:\n\nHave their immature eggs collected from the ovaries without the need for high-dose hormone injections.\n\nHave their eggs matured in a specialized laboratory using a two-step process (biphasic IVM) to improve egg quality.\n\nFollow up with researchers to check the number of embryos created and the safety of the procedure.",[29,82],"Healthy Adult Male","2026-06-15",{"date":85,"type":34},"2026-06-17",{"date":87,"type":34},"2026-06-12",{"date":89,"type":22},"2027-03-30",{"name":91,"class":41},"Mỹ Đức Hospital",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":99,"targetDuration":4,"studyType":23,"phases":101,"briefSummary":102,"conditions":103,"keywords":104,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":42},"100628271","postprandial-triglyceride-concentrations-across-menstrual-cycle-phases-100628271","NCT07459465","Postprandial Triglyceride Concentrations Across Menstrual Cycle Phases","Effect of Menstrual Cycle Phases on Postprandial Triglyceride Concentrations in Healthy Premenopausal Females: A Crossover Study","Inclusion Criteria:\n\n* English or French speaking\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* History or evidence of chronic disease\n* Current use of hypolipemic medication\n* Current use of hormonal contraceptives\n* Current use of antidepressants\n* Current use of anticoagulants\n* Ongoing smoking status\n* Experiencing pregnancy, puerperium, or irregular menstrual cycles",{"count":100,"type":22},12,[54],"The goal of this clinical trial is to investigate the effect of menstrual cycle phases on postprandial triglyceride concentrations in healthy young female adults. The main question it aims to answer is: do postprandial triglyceride concentrations differ between the follicular and luteal phases of the menstrual cycle?\n\nParticipants will: visit the laboratory for a preliminary screening session to assess eligibility, and undergo two experimental sessions consisting of six hours of seated rest following the consumption of a high-fat meal (one session conducted in the early follicular phase, and one session conducted in the mid-luteal phase of the menstrual cycle).",[29],[105,106,107,108],"Triglyceride","Postprandial Lipemia","High-Fat Meal","Menstrual Cycle","2026-05-14",{"date":111,"type":34},"2026-05-19",{"date":113,"type":34},"2026-03-26",{"date":115,"type":22},"2026-08-31",{"name":117,"class":41},"University of Ottawa",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":16,"sex":125,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":23,"phases":130,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":42},"100632463","examining-olive-oil-extract-on-knee-comfort-and-function-100632463","NCT07514013","Examining Olive Oil Extract on Knee Comfort and Function","A 6-Week, Randomized, Double-Blind, Placebo-Controlled Virtual Study Evaluating an Olive Oil Extract on Knee Comfort and Function","Inclusion Criteria:\n\nParticipants must meet all of the following criteria to be eligible for participation:\n\n* Adults aged 40 to 75 years\n* Self-reported knee discomfort for at least 3 months\n* Willing and able to take one study capsule daily for the duration of the study\n* Willing and able to complete digital questionnaires, functional movement tasks, and other study activities using the Alethios platform\n* Willing and able to wear a compatible activity-tracking device throughout the study\n* Willing and able to collect saliva samples at home using a provided kit, if applicable\n* Able to read and understand English\n* Willing to provide informed consent electronically\n\nExclusion Criteria:\n\nParticipants will be excluded if any of the following apply:\n\n* Diagnosis of inflammatory joint disease (e.g., rheumatoid arthritis) or other systemic inflammatory conditions affecting the knee\n* Any current or prior diagnosis from a licensed medical provider of knee disease\n* Knee surgery or significant knee injury within the past 6 months\n* Planned knee surgery during the study period\n* Known allergy or sensitivity to olive-derived products or any component of the study product\n* Current use of investigational drugs or participation in another research study during the study period\n* Any medical condition or circumstance that, in the opinion of the investigator, would make participation unsafe or interfere with study participation or data quality","ALL","40 Years","75 Years",{"count":129,"type":22},168,[54],"The goal of this study is to learn if an olive oil extract works to improve knee pain and discomfort in adults. The main questions it aims to answer are: 1) Does the olive oil extract improve the perceptions of knee pain and discomfort, and 2) Does the olive oil extract improve knee function in adults?\n\nThe main procedures in the study include:\n\n* Screening and informed consent\n* Take one assigned study capsule (supplement or placebo) daily with food for 6 weeks\n* Complete digital questionnaires about your knee pain, stiffness, and function at scheduled times\n* Complete a Day 1 acute assessment and two simple functional movement tests at home as described below\n* If possible, connect a compatible wearable device to allow collection of sleep and physical activity data as detailed below.\n* Collect saliva samples at home using a provided kit at designated timepoints\n* Record any pain medications taken during the study or any side effects",[82,29,133],"Joint Discomfort",[135,136,137,138,139],"olive oil extract","randomized","double-blind","placebo","joint discomfort","2026-04-10",{"date":142,"type":34},"2026-04-15",{"date":144,"type":22},"2026-04",{"date":146,"type":22},"2026-11-01",{"name":148,"class":149},"Applied Food Sciences Inc.","INDUSTRY",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":16,"sex":125,"minAge":18,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":163,"conditions":164,"keywords":168,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":176,"locationsCount":42},"100610787","phase-1-a-study-to-evaluate-the-safety-of-increasing-doses-of-df5112-in-healthy-adults-100610787","NCT07232121","A Study to Evaluate the Safety of Increasing Doses of DF5112 in Healthy Adults","A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Pharmacodynamics of DF5112 in Healthy Adult Participants","DF5112","Key Inclusion Criteria:\n\n* Male or female participants aged 18 to 55 years (inclusive) at the time of informed consent.\n* Body mass index (BMI) between ≥ 18.0 and ≤ 32.0 kg\u002Fm2 and body weight ≥ 45 kg.\n* At the discretion of the Principal Investigator (PI) or designee, in good general health, with no significant medical history, and have no clinically significant abnormalities on physical examination at Screening and\u002For before the first administration of IP.\n* Clinical laboratory values within normal range as specified by the testing laboratory, unless deemed not clinically significant by the PI or designee.\n\nKey Exclusion Criteria:\n\n* History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders that, in the opinion of the PI or designee, are capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data.\n* History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system treated or untreated within the past 5 years, regardless of whether there is evidence of local recurrence or metastases (except for squamous and basal cell carcinoma of the skin or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).\n* History of or evidence of recurrent or chronic bacterial or fungal infections including those of the skin, vagina, oral cavity, etc., or systemic fungal infection.\n* History of unexplained, recurrent infection, or infection requiring treatment with systemic antibiotics within 90 days prior to dosing on Day 1.\n* Active oral infection.\n* Acute illness (e.g. common cold) within 2 weeks prior to Screening, or seasonal influenza or COVID within 4 weeks prior to Screening.\n* History of latent or active tuberculosis that has not been adequately treated, at the discretion of the PI or designee.\n* Positive or inconclusive hepatitis B or hepatitis C based antibody tests at Screening.\n* Positive human immunodeficiency virus (HIV) antibody test at Screening.\n* History of severe allergy, hypersensitivity reaction, or anaphylaxis to drugs or human proteins or components of the study drug formulation used in this study.\n* Any vaccination within 1 month of Day 1 and planned within 1 month post Day 1. Any live or attenuated vaccine within 1 month prior to Day 1 and planned within 3 months post Day 1.","55 Years",{"count":160,"type":22},48,[162],"PHASE1","This is a double-blind, randomized, placebo-controlled, single ascending dose (SAD) study to evaluate safety, tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of DF5112 in healthy adult participants. A total of 48 participants are planned to be randomized into 6 cohorts. Additional cohorts at intermediate dose levels may be evaluated. Each cohort will include 8 healthy participants randomized to receive DF5112 or placebo through intravenous (IV) or subcutaneous (SC) administration. Following dose administration participants will be confined at the clinical research unit for observation for approximately 1 week and then will return for subsequent pre-identified follow up visits through Day 29.",[165,29,82,166,167],"Healthy Participants","Healthy","Volunteer",[169,170],"Healthy Volunteer","Healthy Participant",{"date":172,"type":34},"2026-04-01",{"date":174,"type":34},"2026-01-12",{"date":65,"type":22},{"name":177,"class":149},"Dragonfly Therapeutics",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":23,"phases":188,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":42},"100621154","phase-1-the-effect-of-daily-supplementation-with-humiome-post-lb-on-gastrointestinal-symptoms-in-female-athletes-100621154","NCT07366931","The Effect of Daily Supplementation With Humiome® Post LB on Gastrointestinal Symptoms in Female Athletes","A Randomized, Placebo-controlled, Double-blind Trial on the Effect of Daily Supplementation With Humiome® Post LB on Gastrointestinal Symptoms in Female Athletes","GI-Jane","Inclusion Criteria:\n\n1. Female, cisgender, premenopausal.\n2. Minimum age 18 years.\n3. Regular, natural menstrual cycle (21-35 days in duration), with 9 or more consecutive periods per year, if possible documented with tracker apps, calendars, or other tools.\n4. Willingness and ability to give informed consent and to understand, to participate, and to comply with the clinical study requirements.\n5. Body mass index (BMI) ≥ 18.5 and \\\u003C 24.9 kg\u002Fm2\n6. Agreeing to maintain lifestyle habits during the study (same dietary and physical activity habits)\n7. Having a smartphone and a history of consistent tracking of training and health records via apps.\n8. Having regular GI issues during exercise, preferably also during menstruation. During pre-screening, this will be assessed with a shortened GSRS questionnaire, where participants need to have had, in the month preceding pre-screening, the equivalent of at least a score of 2 in a GSRS focus area (diarrhoea, pain, indigestion).\n9. No relevant self-reported abnormalities from medical history.\n10. Trained athlete (trains at least 3 times per week for more than 1 hour per day and who has been involved in endurance training for at least 2 years in alignment with previous research (Pfeiffer et al., 2010). This will be evaluated by assessing training records (Strava or similar application, certificates of attendance to athletic events, club membership, etc.).\n11. Access to a health-care provider, who can be contacted by the CRO, and who reside in areas with available health services.\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, lactating, or plan to become pregnant before study end.\n2. Individuals with secondary amenorrhea.\n3. Individuals who use hormonal contraceptives during the last 6 months before (and during) the trial.\n4. Individuals who are currently participating in another clinical trial or have participated in a trial within the last two months prior to enrolment.\n5. Tobacco smokers and vapers.\n6. Individuals with acute illness.\n7. Individuals with a current musculoskeletal injury or one within the last month.\n8. Individuals taking probiotic supplements or who have taken probiotics two weeks prior to enrolment.\n9. Individuals controlling chronic diseases with treatments known to alter the intestinal microbiome or to alter GI symptoms, such as certain pain killers, antacids, proton-pump inhibitors, anti-diarrhoeal medication or supplements, and laxatives.\n10. Individuals having received antibiotics treatments within three months of trial start.\n11. Individuals having planned major changes in lifestyle (i.e. diet, weight loss program, exercise level, travelling) during the duration of the study.\n12. Individuals who have any hypersensitivity\u002Fallergy to any of the components of the test product.\n13. Individuals who have planned major elective surgery during the study period.",{"count":187,"type":22},100,[162,189],"PHASE2","Female athletes are often overlooked in scientific research, including the understanding of their digestive system and its impact on overall health, training, and performance. The gastrointestinal (GI) system plays a critical role in supporting digestion, nutrient absorption, and acting as a protective barrier for the body. While there is some knowledge about the differences in GI structure and function between males and females at rest, there is a lack of understanding regarding how these differences manifest during exercise, especially among female athletes and at different phases of the menstrual cycle.\n\nIt has been observed that female athletes commonly report a higher prevalence of GI symptoms compared to males, with many experiencing an increase during menstruation. These symptoms, including bloating, abdominal discomfort, and irregular bowel movements, can significantly disrupt an athlete's training and performance. Elite female athletes have acknowledged that GI symptoms associated with the menstrual cycle have led to altered or disrupted training routines. While these symptoms are commonly recognized to affect a large portion of the female population, few interventions have been studied to assist in managing this discomfort. Some clinicians may direct their patients to take pain-relieving medications without any thoughts on the consequences of chronic use.\n\nOne potential strategy to reduce GI symptoms during endurance exercise is probiotic-postbiotic supplementation. Various probiotic supplements have been shown to effectively decrease diarrhoea, constipation stress, and intestinal permeability, as well as impact immunologic outcomes. Postbiotics differ from probiotics in that they are made from microorganisms that are not alive. They allow the modulation of the composition and function of the gut microbiota and enhance the intestinal barrier to prevent unwanted substances from entering the body proper. While these biotics can relieve lower GI symptoms in irritable bowel syndrome (IBS), there is less consensus regarding their efficacy in modulating exercise-associated GI symptoms. Previous research by Pugh et al., 2019 has demonstrated that four weeks of probiotic supplementation was able to reduce GI symptoms during a marathon race, however this work was predominantly conducted in males and did not take menstrual cycle in consideration. This is important given that symptoms are commonly higher in the early follicular phase when a female experiences their period. Therefore, the aim of this study is to assess the effects of postbiotic supplementation on GI symptomology in female athletes.\n\nThe aim of this present study is to investigate the influence of postbiotic supplementation on menstrual cycle symptoms and exercise-associated GI symptoms in female endurance athletes while exercising compared to symptoms while taking a placebo.",[29,192],"Gastrointestinal Symptoms","NOT_YET_RECRUITING","2026-01-24",{"date":196,"type":34},"2026-01-27",{"date":198,"type":22},"2026-01-01",{"date":200,"type":22},"2026-09-30",{"name":202,"class":41},"Liverpool John Moores University"]